FDA Approved: CEPHALEXIN — Supplemental Application (AvKARE)

View source ↗

Summary

FDA approved a supplemental application for Cephalexin from AvKARE under ANDA 062713, authorizing continued manufacture and marketing of a Cephalexin product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteomyelitis
• Otitis Media
• Respiratory Tract Infections
• Skin and Soft Tissue Infections
• Urinary Tract Infections

Drugs mentioned

• Cephalexin (Cephalexin)

Snippet

SUPPL AP for CEPHALEXIN (CEPHALEXIN)